20. Martin M, Diaz-Rubio E, Casado A et al. Carboplatin: an active drug in metastatic
breast cancer. J Clin Oncol 1992; 10: 433–437.
21. O’Brien ME, Talbot DC, Smith IE. Carboplatin in the treatment of advanced breast
cancer: a phase II study using a pharmacokinetically guided dose schedule. J
Clin Oncol 1993; 11: 2112–2117.
22. Verschraegen CF, Kavanagh JJ, Loyer E et al. Phase II study of carboplatin and
liposomal doxorubicin in patients with recurrent squamous cell carcinoma of the
cervix. Cancer 2001; 92: 2327–2333.
23. Gonçalves A, Braud AC, Viret F et al. Phase I study of pegylated liposomal
doxorubicin (Caelyx) in combination with carboplatin in patients with advanced
solid tumors. Anticancer Res 2003; 23: 3543–3548.
24. Lê LH, Swenerton KD, Elit L et al. Phase II multicenter open-label study of
carboplatin and pegylated liposomal doxorubicin in uterine and cervical
malignancies. Int J Gynecol Cancer 2005; 15: 799–806.
25. Pignata S, Scambia G, Savarese A et al. Safety of a 3-weekly schedule of
carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in
patients with ovarian cancer: preliminary results of the MITO-2 randomized trial.
BMC Cancer 2006; 6: 202.
26. Ferrero JM, Weber B, Geay JF et al. Second-line chemotherapy with pegylated
liposomal doxorubicin and carboplatin is highly effective in patients with
advanced ovarian cancer in late relapse: a GINECO phase II trial. Ann Oncol
2007; 18: 263–268.
27. Pignata S, Scambia G, Pisano C et al. A multicentre phase II study of carboplatin
plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with
advanced or recurrent endometrial carcinoma: the END-1 study of the MITO
(Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies)
group. Br J Cancer 2007; 96: 1639–1643.
28. Power P, Stuart G, Oza A et al. Efficacy of pegylated liposomal doxorubicin (PLD)
plus carboplatin in ovarian cancer patients who recur within six to twelve months:
a phase II study. Gynecol Oncol 2009; 114: 410–414.
29. Pignata S, Lauraine EP, du Bois A, Pisano C. Pegylated liposomal doxorubicin
combined with carboplatin: a rational treatment choice for advanced ovarian
cancer. Critical Rev Oncol Hematol 2010; 73: 23–30.
30. Rapoport BL, Vorobiof DA, Slabber C et al. Phase II study of pegylated liposomal
doxorubicin and carboplatin in patients with platinum-sensitive and partially
platinum-sensitive metastatic ovarian cancer. Int J Gynecol Cancer 2009; 19:
31. Weber B, Lortholary A, Mayer F et al. Pegylated liposomal doxorubicin and
carboplatin in late-relapsing ovarian cancer: a GINECO group phase II trial.
Anticancer Res 2009; 29: 4195–4200.
32. Bafaloukos D, Linardou H, Aravantinos G et al. A randomized phase II study of
carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus
paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative
Oncology Group study. BMC Med 2010; 8: 3.
33. Markman M, Moon J, Wilczynski S et al. Single agent carboplatin versus
carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final
survival results of a SWOG (S0200) phase 3 randomized trial. Gynecol Oncol
2010; 116: 323–325.
34. Stickeler E, Klar M, Watermann D et al. Pegylated liposomal doxorubicin and
trastuzumab as 1stand 2ndline therapy in her2/neu positive metastatic breast
cancer: a multicenter phase II trial. Breast Cancer Res Treat 2009; 117: 599–601.
35. Venturini M, Bighin C, Puglisi F et al. A multicentre Phase II study of non-
pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel
as first-line therapy in metastatic breast cancer. Breast 2010; 19: 333–338.
Annals of Oncology 23: 2605–2612, 2012
Published online 21 August 2012
The impact of second to sixth line therapy on survival
of relapsed ovarian cancer after primary taxane/
L. C. Hanker1*,†, S. Loibl2,†, N. Burchardi3, J. Pfisterer4, W. Meier5, E. Pujade-Lauraine6,
I. Ray-Coquard7, J. Sehouli8, P. Harter9& A. du Bois9on behalf of the AGO and
GINECO study group
1Department of Gynecology and Obstetrics, Johann Wolfgang Goethe-University, Frankfurt am Main;2German Breast Group Forschungs GmbH, Neu Isenburg,
Department of Gynecology and Obstetrics Klinikum Offenbach, Offenbach am Main;3Coordinating Center for Clinical Trials, Philipps-University, Marburg;4Department of
Gynecology and Obstetrics, Städtisches Klinikum, Solingen;5Department of Gynecology and Obstetrics, Evangelical Hospital, Duesseldorf, Germany;6Department of
Oncology, Hôpital Hôtel-Dieu, Paris;7Department of Oncology, Centre Léon Bérard, Lyon, France;8Department of Gynecology, Charité/Campus Virchow Klinikum
Medical University, Berlin;9Department of Gynecology and Gynecologic Oncology, Kliniken Essen Mitte, Essen, Germany
Received 13 February 2012; revised 18 May 2012; accepted 21 May 2012
Background: Despite recent progress in the treatment of ovarian cancer, the majority of patients eventually relapse.
There is little information on the effectiveness of chemotherapy in higher treatment lines.
Patients and methods: Characterization of the second to sixth line therapy and its effects on survival was carried
out, based on data of n= 1620 patients from three large randomized phase III trials investigating primary therapy.
†These authors contributed equally to the work.
*Correspondence to: Dr L. C. Hanker, Department of Obstetrics and Gynecology,
J.W. Goethe-University, Theodor-Stern-Kai 7, D-60590 Frankfurt, Germany.
Tel: +49-69-6301-7024; Fax: +49-69-6301-83469; E-mail: email@example.com
Annals of Oncology
© The Author 2012. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
All rights reserved. For permissions, please email: firstname.lastname@example.org.
by guest on October 30, 2015
advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR
and GINECO. J Natl Cancer Inst 2006; 98: 1036–1045.
13. du Bois A, Weber B, Rochon J et al. Arbeitsgemeinschaft Gynaekologische
Onkologie; Ovarian Cancer Study Group; Groupe d’Investigateurs Nationaux pour
l’Etude des Cancers Ovariens. Addition of epirubicin as a third drug to
carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a
prospectively randomized gynecologic cancer intergroup trial by the
Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group
and the Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens.
J Clin Oncol 2006; 24: 1127–1135.
14. Markman M. Viewing ovarian cancer as a ‘chronic disease’: what exactly does
this mean? Gynecol Oncol 2006; 100(2): 229–230.
15. Monk BJ, Herzog TJ, Kaye SB et al. Trabectedin plus pegylated liposomal
Doxorubicin in recurrent ovarian cancer. J Clin Oncol 2010; 28(19):
16. Clinical Practice Guidelines in OncologyTM: Ovarian Cancer Including Fallopian
Tube Cancer and Primary Peritoneal Cancer, Version 2.2011. National
Comprehensive Cancer Network (NCCN) 2011. Available at: http://www.nccn.org/
professionals/physician_gls/pdf/ovarian.pdf. Accessed February 15, 2011.
17. du Bois A, Rochon J, Lamparter C et al. Die Qualität der Rezidivtherapie beim
Ovarialkarzinom in Deutschland Eine Qualitätssicherungserhebung im Rahmen
des Aktionsprogramms der AGO Kommission OVAR (QS-OVAR). Frauenarzt 2009;
18. Chiyoda T, Tsuda H, Nomura H et al. Effects of third-line chemotherapy for
women with recurrent ovarian cancer who received platinum/taxane regimens as
first-line chemotherapy. Eur J Gynaecol Oncol 2010; 31(4): 364–368.
19. Nishio S, Katsumata N, Matsumoto K et al. Usefulness of third-line
chemotherapy for women with recurrent ovarian, fallopian tube, and primary
peritoneal cancer who receive platinum/taxane regimens as first-line therapy.
J Cancer Res Clin Oncol 2009; 135(4): 551–557.
20. Vergote I, Finkler N, del Campo J et al. Phase 3 randomised study of
canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or
topotecan as third-line therapy in patients with platinum-refractory or -resistant
ovarian cancer. Eur J Cancer 2009; 45(13): 2324–2332.
21. Sehouli J, Stengel D, Harter P et al. Topotecan weekly versus conventional 5-day
schedule in patients with platinum-resistant ovarian cancer: a randomized
multicenter phase II trial of the North-Eastern German Society of
Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol 2011; 29(2):
22. Mutch DG, Orlando M, Goss T et al. Randomized phase III trial of gemcitabine
compared with pegylated liposomal doxorubicin in patients with platinum-
resistant ovarian cancer. J Clin Oncol 2007; 25(19): 2811–2818.
23. Ferrandina G, Ludovisi M, Lorusso D et al. Phase III trial of gemcitabine
compared with pegylated liposomal doxorubicin in progressive or recurrent
ovarian cancer. J Clin Oncol 2008; 26(6): 890–896.
24. Gordon AN, Fleagle JT, Guthrie D et al. Recurrent epithelial ovarian carcinoma: a
randomized phase III study of pegylated liposomal doxorubicin versus topotecan.
J Clin Oncol 2001; 19: 3312–3322.
25. Findley MK, Lee H, Seiden MV et al. Do more lines of chemotherapy make you live
longer? Treamtent for ovarian cancer comparing cohorts of patients 1989–90 with
1995–6 in multivariate analysis for survival. J Clin Oncol 2005; 23 (Suppl): 16S.
26. Brown D, Roberts JA, Elkins TE et al. Hard choices: the gynecologic cancer
patient’s end-of-life preferences. Gynecol Oncol 1994; 55(3 Pt 1): 355–362.
27. Penson RT, Dignan F, Seiden MV et al. Attitudes to chemotherapy in patients
with ovarian cancer. Gynecol Oncol 2004; 94(2): 427–435.
28. Donovan KA, Greene PG, Shuster JL et al. Treatment preferences in recurrent
ovarian cancer. Gynecol Oncol 2002; 86(2): 200–211.
29. Markman M. Why study third-, fourth-, fifth-,…line chemotherapy of ovarian
cancer? Gynecol Oncol 2001; 83(3): 449–450.
30. Blackledge G, Lawton F, Redman C et al. Response of patients in phase II
studies of chemotherapy in ovarian cancer: implications for patient treatment and
the design of phase II trials. Br J Cancer 1989; 59(4): 650–653.
31. Gore ME, Fryatt I, Wiltshaw E et al. Treatment of relapsed carcinoma of the ovary
with cisplatin or carboplatin following initial treatment with these compounds.
Gynecol Oncol 1990; 36(2): 207–211.
32. Markman M, Rothman R, Hakes T et al. Second-line platinum therapy in patients
with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991; 9(3):
33. Harrison ML, Gore ME, Spriggs D et al. Duration of second or greater complete
clinical remission in ovarian cancer: exploring potential endpoints for clinical
trials. Gynecol Oncol 2007; 106(3): 469–475.
34. Hoskins P, Tu D, James K et al. Factors predictive of survival after first relapse or
progression in advanced epithelial ovarian carcinoma: a prediction tree analysis-
derived model with test and validation groups. Gynecol Oncol 1998; 70(2): 224–230.
35. Markman M, Markman J, Webster K et al. Duration of response to second-line,
platinum-based chemotherapy for ovarian cancer: implications for patient
management and clinical trial design. J Clin Oncol 2004; 22(15): 3120–3125.
Annals of Oncology
| Hanker et al.Volume 23 | No. 10 | October 2012
by guest on October 30, 2015